-

Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

DexCom, Inc.:
Sean Christensen
Vice President – Finance and Investor Relations
investor-relations@dexcom.com
(858) 200-0200

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

DexCom, Inc.:
Sean Christensen
Vice President – Finance and Investor Relations
investor-relations@dexcom.com
(858) 200-0200

More News From DexCom, Inc.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo...

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer...

Dexcom Appoints Glenn Boehnlein to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology...
Back to Newsroom